VivoSeq
Other

Smokers

0

Pipeline Programs↗

3

Active Trials↗

6

Companies Involved↗

Smokers is an early-stage landscape with 0 programs across 6 companies. The most active players are GSK, Pfizer, Nabi Biopharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

91/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalN

Nabi Biopharmaceuticals

0 programs

PreclinicalA

Alexza Pharmaceuticals, Inc.

0 programs

PreclinicalE

Engage Therapeutics, Inc.

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

69

clinical trials

Completed58 · 84%
Terminated5 · 7%
Recruiting3 · 4%
Unknown status2 · 3%
Withdrawn1 · 1%

Clinical Trials

Trial Activity

69 trials

Inhaled RB042 in Healthy Adult Volunteers and Healthy Adult Smokers
Recruiting·RRAGE Bio·Phase 1·NCT07285122·90 enrolled
Effects of a Specific Substance in Smokers
Recruiting·OOregon Health and Science University·N/A·NCT04281979·60 enrolled
Switching to E-cigarettes in Smokers Not Interested in Quitting
Recruiting·UUniversity of Kansas Medical Center·Phase 3·NCT05703672·500 enrolled
A Comparability Study of the Phase 3 Lot and a Single Commercial Lot of NicVAX in Healthy Adult Smokers
Completed·NNabi Biopharmaceuticals·Phase 3·NCT01375933·260 enrolled
Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers
Completed·—·Phase 2·NCT01926626·76 enrolled
Study to Evaluate Effect of Food on Bioavailability of Single 3 mg Tablet and Pharmacokinetics (PK) of Multiple 3 mg Doses in Healthy Adult Smokers
Completed·AAchieve Life Sciences·Phase 1·NCT05981768·30 enrolled
Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy Smokers
Completed·AAchieve Life Sciences·Phase 1·NCT05566288·27 enrolled
Staccato Loxapine PK in Smokers and Nonsmokers
Completed·AAlexza Pharmaceuticals, Inc.·Phase 1·NCT00873769·35 enrolled
Use of Pharmacotherapy to Reduce Cue-responsiveness in Smokers
Completed·CCentre for Addiction and Mental Health·Phase 1·NCT00133757·50 enrolled
Telephone Counseling and the Distribution of Nicotine Patches to Smokers
Completed·UUniversity of California, San Diego·Phase 3·NCT00851357·4,200 enrolled
Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status
Completed·MMilton S. Hershey Medical Center·N/A·NCT01928719·280 enrolled
Naltrexone and Patch for Smokers
Completed·US Department of Veterans Affairs·N/A·NCT00018213
Single-dose Nicotine Pharmacokinetics With Three Oral Nicotine Replacement Products. A Study in Healthy Smokers.
Completed·MMcNeil AB·N/A·NCT01234792·24 enrolled
Strategies to Promote Cessation in Smokers Who Are Not Ready To Quit
Completed·UUniversity of Virginia·N/A·NCT02905656·903 enrolled
Understanding Disparities in Quitting in African American and White Smokers
Completed·—·Phase 4·NCT01836276·449 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)